# TASK-012 final independent Architecture Manager review

Date: 2026-11-05

Task: TASK-012  
Reviewer role: MANAGER: Architecture  
Independent review: YES  
Decision: APPROVED

## Review scope

Read-only review of the TASK-012 brief and canonical status records,
initialization protocol, SPEC-008, SPEC-001, project schema and cross-reference
rules, focused tests, verification report, and relevant TASK-020 approval and
collision policies.

## Acceptance criteria

- **AC-01 — PASS.** Greenfield, brownfield, already-initialized, and
  reconciliation flows have concrete scenarios.
- **AC-02 — PASS.** Observed facts, confirmed facts, assumptions, and unknowns
  are separated. Required scalars are confirmed rather than invented;
  non-blocking unknowns remain explicit, and status semantics follow R-PROJ-02.
- **AC-03 — PASS.** Summary confirmation and separate write-plan approval are
  explicit gates.
- **AC-04 — PASS.** `CREATE`, `MERGE`, `SKIP`, and `CONFLICT` preview behavior,
  exact-path overwrite approval, and all-or-nothing conflict handling are
  specified.

The purpose mapping explicitly uses a confirmed one-sentence purpose for both
`project.description` and `purpose.summary` by default, while asking for
separate confirmed values when requested. `partial` retains only non-blocking
unknowns; `complete` requires an empty unknowns array. Pre-approval `pending`
state remains a draft rather than canonical project data. The document
specifies behavior only and makes no runtime initializer claim.

Cancellation and resumption are covered by concrete scenarios. Collision and
approval rules align with TASK-020, including preserving unknown files,
blocking all writes on unresolved conflicts, and requiring exact-path approval
for an overwrite.

## Verification reviewed

Independently ran
`python3 -m unittest discover -s tests -p 'test_initialization_spec.py' -v`:
**PASS — 9 tests**.

The other repository regression results in the verification report were
reviewed; they are rerun by the evidence-gated completion command.

No findings or blockers remain.
